A5052236281- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Endometriosis Research and Treatment
- Mental Health Research Topics
- Intraperitoneal and Appendiceal Malignancies
- Psychotherapy Techniques and Applications
- BRCA gene mutations in cancer
- Treatment of Major Depression
- Cervical Cancer and HPV Research
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Cancer Immunotherapy and Biomarkers
- Uterine Myomas and Treatments
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Sarcoma Diagnosis and Treatment
- Reproductive Biology and Fertility
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Cancer-related molecular mechanisms research
- Psychiatric care and mental health services
- Genetic factors in colorectal cancer
- Cancer, Hypoxia, and Metabolism
- Schizophrenia research and treatment
University of Rochester Medical Center
2016-2025
University of Rochester
1959-2024
Cancer Institute (WIA)
2019-2023
Canada's Michael Smith Genome Sciences Centre
2014-2023
Memorial Sloan Kettering Cancer Center
2015-2023
Sidney Kimmel Cancer Center
2023
Johns Hopkins University
2023
Indiana University – Purdue University Indianapolis
2023
Michigan Cancer Research Consortium
2023
Indiana University Health
2023
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients recurrent ovarian cancer after platinum-based chemotherapy, regardless the presence or absence BRCA mutations. The efficacy niraparib in newly diagnosed advanced a response to first-line chemotherapy is unknown.In this randomized, double-blind, phase 3 trial, we randomly assigned 2:1 ratio receive placebo once daily...
Metacognitive awareness is a cognitive set in which negative thoughts/feelings are experienced as mental events, rather than the self. The authors hypothesized that (a) reduced metacognitive would be associated with vulnerability to depression and (b) therapy (CT) mindfulness-based CT (MBCT) reduce depressive relapse by increasing awareness. They found accessibility of sets cues was less vulnerable group (residually depressed patients) nondepressed controls; predicted residually patients;...
<h3>Background</h3> Previous studies indicate that depressed patients with partial remission and residual symptoms following antidepressant treatment are common have high rates of relapse. There is evidence cognitive therapy may reduce relapse in depression. <h3>Methods</h3> One hundred fifty-eight recent major depression, partially remitted (mean daily doses equivalent to 185 mg amitriptyline or 33 fluoxetine) but 2 18 months' duration, were included a controlled trial. Subjects randomized...
Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to remains unclear. Download a PDF the Research Summary. In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) stage IVB recurrent in 1:1 ratio receive placebo along combination therapy administration was planned 6 cycles every weeks, followed by up 14 maintenance weeks. were stratified...
It is often difficult to distinguish a benign pelvic mass from malignancy and tools help referring physician are needed. The purpose of this study was validate the Risk Ovarian Malignancy Algorithm in women presenting with mass.This prospective, multicenter, blinded clinical trial that included who presented gynecologist, family practitioner, an internist, or general surgeon adnexal mass. Serum HE4 CA 125 were determined preoperatively. A score calculated classified patients into high-risk...
PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed activity two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS AND METHODS NRG-GY004 an open-label, randomized, phase III trial conducted in United States and Canada. Eligible patients had high-grade serous endometrioid cancer. Patients were randomly assigned 1:1:1...
JCO
To report updated long-term efficacy and safety from the double-blind, placebo-controlled, phase 3 PRIMA/ENGOT-OV26/GOG-3012 study (NCT02655016).Patients with newly diagnosed advanced ovarian cancer complete or partial response (CR PR) to first-line platinum-based chemotherapy received niraparib placebo once daily (2:1 ratio). Stratification factors were best regimen (CR/PR), receipt of neoadjuvant (yes/no), homologous recombination deficiency (HRD) status (deficient [HRd]/proficient [HRp]...
This study examined the cognitive mediation of relapse prevention by therapy (CT) in a trial 158 patients with residual depression. Scores based on agreement item content 5 questionnaires depression-related cognition provided no evidence for mediation. A measure form response to those questionnaires, number times used extreme categories ("totally agree" and "totally disagree"), showed significant substantial prediction relapse, differential CT. conformity mediational criteria. CT reduced...
There has been relatively little attention given to the issue of positive cognition in psychological research and therapy. This paper explores reasons for this neglect presents empirical conceptual support importance mental health. Evidence is presented that negative aspects experience are mediated by separate systems rather than being opposite ends a single dimension. We then review describes potential disorders, especially recovery relapse depression. Finally, we present suggestions...
BACKGROUND A 2‐stage ovarian cancer screening strategy was evaluated that incorporates change of carbohydrate antigen 125 (CA125) levels over time and age to estimate risk cancer. Women with high‐risk scores were referred for transvaginal ultrasound (TVS). METHODS single‐arm, prospective study postmenopausal women conducted. Participants underwent an annual CA125 blood test. Based on the Risk Ovarian Cancer Algorithm (ROCA) result, triaged next test (low risk), repeat in 3 months...
In this article, the development of female breast, as well functional anatomy, blood supply, innervation and lymphatic drainage are described. A thorough understanding breast anatomy is an important adjunct to a meticulous clinical examination. Breast examination complex skill involving key maneuvers, including careful inspection palpation. Clinical can provide opportunity for clinician educate patients about their cancer, its symptoms, risk factors, early detection, normal composition,...
To assess safety and efficacy of niraparib + bevacizumab as a first-line maintenance therapy for patients with newly diagnosed advanced ovarian cancer.This multicenter, phase II, single-arm, open-label study enrolled adult stage IIIB to IV ovarian, fallopian tube, or primary peritoneal cancer (NCT03326193). Patients were required have an attempt at debulking surgery complete response, partial no evidence disease following first-line, platinum-based chemotherapy ≥3 cycles bevacizumab. The...
Abstract Purpose: The efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline–BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer. Patients Methods: PARP inhibitor–naïve women aged ≥18 years non-gBRCAm cancer, ECOG performance status 0–2, ≥3 prior lines therapy received 30 mg once daily 200 twice this single-arm, multicenter, phase IIb trial. primary endpoint was objective response rate (ORR) by independent...